Effects of hydrochlorothiazide, amiloride, and lisinopril on the metabolic response to adrenaline infusions in normal subjects.
Twelve healthy male volunteers were given adrenaline infusions, 0.05 microgram/kg body weight/min over 120 minutes in order to achieve serum adrenaline concentrations comparable with those seen in acute myocardial infarction. The infusions were given on four occasions, at intervals of at least 4 weeks. Before the infusions the subjects were given, in random order, 14 days of pretreatment with placebo, hydrochlorothiazide 50 mg once daily, amiloride 10 mg once daily, or lisinopril 20 mg once daily. The adrenaline infusion induced a drop in serum potassium of the same magnitude in all four groups, with the lowest absolute value after hydrochlorothiazide because of the lowest pre-adrenaline level. The infusion-induced decreases in serum calcium and magnesium were of the same magnitude in all groups, with the absolute calcium being least low in the hydrochlorothiazide group because of the highest preinfusion value. Preinfusion serum urate was highest after hydrochlorothiazide and fell during the adrenaline infusion in all groups, although not significantly. Blood glucose increased during the adrenaline infusion in all groups, but significantly more after hydrochlorothiazide and amiloride than after lisinopril. Heart rate increased during the adrenaline infusion in all groups but least after lisinopril. QTc preinfusion was longer after hydrochlorothiazide than after amiloride and placebo, but the infusion-induced prolongation of QTc was of the same magnitude in all pretreatment groups. Since our results were obtained in short-term experiments in normal subjects, their clinical relevance is questionable, but they support the view that ACE inhibitors may have certain metabolic advantages over diuretics.
Hansen
O
O
Cardiology Section, General Hospital, Malmö, Sweden.
Johansson
B W
BW
D000328:Adult; D000584:Amiloride / Q000008:administration & dosage / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology*; D004562:Electrocardiography; D004837:Epinephrine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous; D017706:Lisinopril; D008274:Magnesium / Q000097:blood; D008297:Male; D011188:Potassium / Q000097:blood; D011897:Random Allocation; D012709:Serum Albumin / Q000032:analysis; D014527:Uric Acid / Q000097:blood
D000959:Antihypertensive Agents; D001786:Blood Glucose; D004151:Dipeptides; D012709:Serum Albumin; D006852:Hydrochlorothiazide; D014527:Uric Acid; D000584:Amiloride; D003404:Creatinine; D017706:Lisinopril; D008274:Magnesium; D011188:Potassium; D002118:Calcium; D004837:Epinephrine